Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer.
Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer.
复制标题
DOI：
10.1038/s41598-023-34690-y
复制
发表时间：
2023-05-24
影响因子：
4.6
通讯作者：
中科院分区：
文献类型：
--
作者：
我们试图调查早期结直肠癌（CRC）患者内脏肥胖与疾病复发和生存之间的关系。我们还想检查这种关联是否存在，是否受二甲双胍使用的影响。手术治疗的I/II期结直肠癌腺癌患者被确定。采用L3层CT VFI（内脏脂肪指数）作为内脏肥胖的度量标准，计算为内脏脂肪占总脂肪面积的比例。n = 492。53%为男性，90%为白种人，35%为I期疾病，14%使用二甲双胍。20.3%的患者在中位随访56个月后复发。在多变量模型中，VFI与RFS和OS均相关，但与BMI无关。RFS的最终多变量模型包括VFI和二甲双胍的相互作用项（p = 0.04）。亚组分析证实了这一结果，显示VFI增加与较差的RFS相关（p = 0.002），未使用二甲双胍的OS （p < 0.001）和仅使用二甲双胍的VFI最高组与较好的RFS相关（p = 0.01）。内脏肥胖与I/II期CRC的复发风险和较差的生存率相关，但与BMI无关。有趣的是，这种关联受到二甲双胍使用的影响。
We sought to investigate the association between visceral obesity with disease recurrence and survival in early-stage colorectal cancer (CRC) patients. We also wanted to examine if such an association, if exists, is influenced by metformin use. Stage I/II CRC adenocarcinoma patients treated surgically were identified. L3 level CT VFI (visceral fat index) was used as a metric of visceral obesity and was calculated as the proportion of total fat area composed of visceral fat. N = 492. 53% were males, 90% were Caucasians, 35% had stage I disease, and 14% used metformin. 20.3% patients developed a recurrence over a median follow-up of 56 months. VFI was associated with both RFS and OS in a multivariate model, but not BMI. The final multivariate model for RFS included an interaction term for VFI and metformin (p = 0.04). Confirming this result, subgroup analysis showed an increasing VFI was associated with a poor RFS (p = 0.002), and OS (p < 0.001) in metformin non-users only and metformin use was associated with a better RFS only in the top VFI tertile (p = 0.01). Visceral obesity, but not BMI, is associated with recurrence risk and poorer survival in stage I/II CRC. Interestingly, this association is influenced by metformin use.
登录
查看更多内容
影响因子：
5.2
作者：
Higurashi T;Nakajima A
通讯作者：
Nakajima A
DOI：
10.1001/jama.2014.732
发表时间：
2014-02-26
期刊：
JAMA
影响因子：
--
作者：
Ogden CL;Carroll MD;Kit BK;Flegal KM
通讯作者：
Flegal KM
影响因子：
5.7
作者：
Saito A;Kitayama J;Horie H;Koinuma K;Ohzawa H;Yamaguchi H;Kawahira H;Mimura T;Lefor AK;Sata N
通讯作者：
Sata N
影响因子：
158.5
作者：
Sauer, R;Becker, H;Raab, R
通讯作者：
Raab, R
影响因子：
13.8
作者：
Fleming CA;O'Connell EP;Kavanagh RG;O'Leary DP;Twomey M;Corrigan MA;Wang JH;Maher MM;O'Connor OJ;Redmond HP
通讯作者：
Redmond HP